ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,868.55
-0.22%
Dow Jones
42,392.27
-0.36%
US Dollar vs MXN
20.5479
-0.29%
Brent Oil
76.085
0.30%
Bitcoin
96,804.38
-0.10%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NYSE
  6. Qiagen NV (QGEN)

  7. Qiagen NV (QGEN) Noticias

QGEN

Qiagen NV (QGEN)

Qiagen NV
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NYSE:QGEN
FechaHoraFuenteTítuloSímboloCompañía
12/12/202415:05Business WireQIAGEN führt KI-Erweiterung für Ingenuity Pathway Analysis zur automatisierten Interpretation biologischer Daten einNYSE:QGENQiagen NV
12/12/202415:05Business WireQIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological DataNYSE:QGENQiagen NV
05/12/202415:05Business WireQIAGEN erreicht Meilenstein: Über 1.000 platzierte EZ2 Connect-Systeme zur Probenvorbereitung treiben Laborautomatisierung voranNYSE:QGENQiagen NV
05/12/202415:05Business WireQIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory AutomationNYSE:QGENQiagen NV
28/11/202405:00Business WireQIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine TestingNYSE:QGENQiagen NV
28/11/202405:00Business WireQIAGEN stärkt QIAstat-Dx mit neuem Standort in Barcelona zur Wachstumsbeschleunigung bei Tests für Infektionskrankheiten und PräzisionsmedizinNYSE:QGENQiagen NV
27/11/202415:05GlobeNewswire Inc.QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysisNYSE:QGENQiagen NV
12/11/202415:05GlobeNewswire Inc.QIAGEN collaborates with McGill University to advance microbiome researchNYSE:QGENQiagen NV
07/11/202410:46Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNYSE:QGENQiagen NV
06/11/202415:05GlobeNewswire Inc.QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlookNYSE:QGENQiagen NV
04/11/202400:30GlobeNewswire Inc.QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnosticsNYSE:QGENQiagen NV
29/10/202401:30GlobeNewswire Inc.QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatmentNYSE:QGENQiagen NV
10/10/202415:05GlobeNewswire Inc.QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applicationsNYSE:QGENQiagen NV
10/10/202406:41GlobeNewswire Inc.QIAGEN N.V. to release results for Q3 2024 and hold webcastNYSE:QGENQiagen NV
07/10/202415:05GlobeNewswire Inc.Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killerNYSE:QGENQiagen NV
30/09/202415:05GlobeNewswire Inc.QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncologyNYSE:QGENQiagen NV
26/09/202415:05GlobeNewswire Inc.QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assaysNYSE:QGENQiagen NV
25/09/202415:05GlobeNewswire Inc.PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samplesNYSE:QGENQiagen NV
23/09/202415:05GlobeNewswire Inc.QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy databaseNYSE:QGENQiagen NV
18/09/202415:05GlobeNewswire Inc.QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platformNYSE:QGENQiagen NV
12/09/202415:05GlobeNewswire Inc.QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programsNYSE:QGENQiagen NV
11/09/202417:18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:QGENQiagen NV
04/09/202415:05GlobeNewswire Inc.QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer’s diseaseNYSE:QGENQiagen NV
03/09/202415:16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:QGENQiagen NV
28/08/202415:05GlobeNewswire Inc.QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in chronic diseasesNYSE:QGENQiagen NV
06/08/202415:05GlobeNewswire Inc.Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%NYSE:QGENQiagen NV
31/07/202415:06GlobeNewswire Inc.QIAGEN delivers solid performance and exceeds outlook for Q2 2024NYSE:QGENQiagen NV
08/07/202415:05GlobeNewswire Inc.QIAGEN to enhance the identification of human remains of Indigenous people and African AmericansNYSE:QGENQiagen NV
02/07/202408:29GlobeNewswire Inc.QIAGEN N.V. to release results for Q2 2024 and hold webcastNYSE:QGENQiagen NV
27/06/202415:05GlobeNewswire Inc.QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in childrenNYSE:QGENQiagen NV
 Showing the most relevant articles for your search:NYSE:QGEN

Su Consulta Reciente

KUCN
DARBTC
Dalarnia
NYSE
EVF
Eaton Vance Senior Income
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados